Coordinated Drug Development As An Execution Framework

In distributed drug development models, each phase transition requires documentation reconciliation, revalidation of technical assumptions, and a transfer of accountability. Alignment is rebuilt repeatedly, and that repetition carries measurable costs: timing variability, duplicated effort, and gaps in cross-phase visibility that become most acute at scale-up and commercial transitions.

The structural alternative this white paper examines is coordinated execution, where clinical research, CMC development, manufacturing, and supply operate within a shared governance framework rather than across sequential handoffs. The paper explores three dimensions of that model: lifecycle connectivity that preserves technical context across phases, speed advantages that emerge when planning assumptions are shared earlier across functions, and scalable oversight that remains stable as programs expand across regions and regulatory environments.

Supporting analysis from the Tufts Center for the Study of Drug Development quantifies the financial impact of this approach relative to traditional distributed execution. Explore the full paper to assess the case for structural alignment across the development lifecycle.